Arcturus Therapeutics Q3 2025 Earnings Report

Arcturus Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.09
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Arcturus Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $17.47 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Arcturus Therapeutics Announcement Details

• Quarter: Q3 2025
• Date: 11/6/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, November 6, 2025
• Conference Call Time: 4:30PM ET

Arcturus Therapeutics (NASDAQ:ARCT) is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore. Additional preclinical programs are directed toward addressing other metabolic disorders and infectious diseases. Arcturus’s research and development efforts focus on leveraging mRNA’s capacity for rapid design and production, aiming to reduce development timelines compared with traditional biologics.

Headquartered in San Diego, California, Arcturus maintains research and manufacturing facilities both in the United States and in Singapore, reflecting its commitment to global collaboration and supply chain resilience. The Singapore facility supports the company’s vaccine development programs and provides clinical-scale manufacturing capabilities to meet regulatory requirements in multiple jurisdictions.

Since going public in 2018, Arcturus has been led by Chief Executive Officer Joseph E. Payne, who brings experience from several biotechnology and pharmaceutical roles. Under his leadership, the company has forged partnerships with academic institutions and contract manufacturing organizations to advance its clinical programs. Arcturus continues to explore new applications of its mRNA platform through collaborations and licensing agreements aimed at expanding its pipeline and demonstrating the versatility of mRNA-based therapeutics.